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All cellular organisms require the ability to integrate and respond to intra and extracellular signals. In eukaryotic organisms, complex signaling machineries have been developed
for this purpose. The Nuclear Hormone Receptor (NR) superfamily of proteins is one such
mechanism. This family encompasses a large number of structurally and functionally similar
proteins that regulate a wide variety of physiological processes, such as toxin clearance, growth
and development, and homeostasis, through activation of transcription of target genes. This
thesis will deal primarily with biophysical, biochemical, and structural investigations into the
Nuclear Receptor family of proteins, with the goal of furthering our understanding of the
structures and functions of these proteins.
The discovery of hormones and steroids in the early 20th century catalyzed the
investigations that would eventually lead to the discovery of Nuclear Receptors. Hormones and
steroids were first analyzed for the large-scale effects that could be observed in organisms upon
their addition; a seminal study involved attributing early amphibian metamorphosis to the
addition of mammalian thyroid extracts. Further investigations revealed significant effects
potentiated by other hormone and steroid molecules, including cortisone and estrogen. The
biological significance of steroid and hormone molecules led to a massive effort to organically
synthesize these molecules in the lab, which led to the famous race between Woodward and
Robinson to achieve a total synthesis of Cholesterol. These successes furthered the
pharmacological interest in the function of hormones and steroids, and by 1961 Jensen had
radioactively tracked the hormone oestradiol-17β to the nucleus, in complex with a protein. This
soon led to a new model for the action of hormones and steroids, whereby the function of the
ligand was to interact with and thereby activate a receptor protein. Improvements in technology
that spurred the molecular biology revolution also led to the cloning of the Glucocorticoid and
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Thyroid Hormone Receptor in the lab of Ron Evans, and the Estrogen Receptor in the labs of
Pierre Chambon and Geoffrey Greene in the mid 1980’s, which led to a rapid increase in the
understanding of NR structure and function. Since these seminal experiments, a great many NR
receptors have been recombinantly purified and examined structurally and functionally, both
individually and in various complexes with their physiological partners and ligands. Current
work focuses on ever larger complexes with full-length receptors and their interacting partners to
more comprehensively understand their physiological functions.
Though many questions remain, a great deal has been uncovered about the structure of
NRs. It is now known that NRs are characteristically modular proteins with several domains.
Most receptors contain six domains: a highly variable N-terminal domain containing an
Activation Function 1 (AF-1) domain, a well-conserved zinc-finger DNA-binding Domain
(DBD), a hinge region, a Ligand Binding Domain (LBD), and an Activation Function 2 (AF-2).

Fig 1.1: General structural organization of nuclear receptors. Source:
http://upload.wikimedia.org/wikipedia/commons/3/3e/Nuclear_Receptor_Structure.png
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The structures of the individual DBDs and LBDs have been studied intensively by x-ray
crystallography and biochemical assays, though larger fragments and full-length studies of
nuclear receptors have been limited by the difficulty of recombinant purification and structural
characterization. Indeed, only recently have DBD-LBD complexes been successfully analyzed
by crystallography, scattering, or cryo-EM. These analyses have revealed a general paradigm for
the function of NRs: ligand activation by binding in the LBD causes dissociation of NRs from
their co-repressor complexes, and subsequent translocation (if necessary) to their DNA promoter
sequences as monomers, dimers or heterodimers, upon which the receptors bind coactivator
molecules to initiate the assembly of the transcription machinery. The dimerization interface,
which is usually composed of approximately three helices from each receptor subunit, mediates
allosteric communication between the dimer subunits. The mechanism of coactivator binding is
fairly well understood in individual cases. In general, ligand binding to the ligand-binding cavity
induces a conformational change that pulls Helix 12 from a flexible conformation extending
from the receptor surface to a static conformation lying along the receptor surface. This
conformational change dissociates corepressor complexes and creates a coactivator interaction
surface that consists of a hydrophobic groove with “charge clamp” residues to bind to specific
residues in cognate coactivator proteins. The LBDs also contain the dimerization interface in
most cases, whereby homodimerization or heterodimerization may occur.
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Fig 1.2: Diagram of helices in the DBD and LBD of a Retinoid X Receptor : Retinoic Acid Receptor heterodimer.
The coactivator-interaction surface near H12 and the dimerization interface near H10 are clearly shown. Source:
http://www.nature.com/nrd/journal/v6/n10/fig_tab/nrd2398_F1.html

The structure of the LBD, therefore, determines specificity for ligand, coactivator, and other NR
interactions, and this structure is therefore relatively variable among the different members of the
NR superfamily. The DBD is by comparison a more conserved subunit, and is most important
for its zinc-finger DNA recognition function. The DBD connects to the LBD via a short, flexible
hinge domain whose functional properties remain unclear, despite being evidently significant.
Most NRs also contain a variably-size N-terminal domain with an AF-1. These domains are very
weakly conserved throughout the superfamily, and their high degree of flexibility has precluded
extensive study. While it is understood that this N-terminal domain is important in regulating
transcription, mechanisms to explain its function are not yet available.
A detailed atomic view of both the LBD and DBD is necessary to understand much of
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modern NR research. Many NR LBDs have now been crystallized, and all reveal a globular
structure consisting of approximately 12 α-helices. These helices form a set of three antiparallel
sheets, the interior of which contains the ligand-binding pocket. These ligand binding pockets
determine their specificity primarily through hydrophobic interactions, though hydrogen bonding
interactions and specific residue interactions are often critical in determining the orientation and
affinity for the precise ligand required.

Fig 1.3: Glucocorticoid receptor with dexamethasone bound in the ligand binding pocket. Several charge clamps are
indicated by yellow lines. Source:http://upload.wikimedia.org/wikipedia/commons/f/f0/Glucocorticoid_receptor.png

The AF-2 domain consists largely of Helix 12, though other helices are also involved. Upon
binding of agonist ligand, Helix 12 rearranges to form a coactivator interaction surface.
Coactivators with helical LXXLL sequences are able to bind to these surfaces primarily through
hydrophobic interactions, with “charge clamp” interactions at each end of the helix mediated
usually by glutamate and lysine residues on the NR. When bound to antagonist ligand or
unliganded, most receptors either cannot form the coactivator interaction surface or have a
corepressor outcompeting the coactivator for the surface. Therefore, ligand binding is a critical
mediator of NR activity.
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Fig 1.4: Conformation change associated with the binding of ligands and its physiological impact.
Source:http://upload.wikimedia.org/wikipedia/commons/thumb/d/d4/NR_mechanism.png/480pxNR_mechanism.png

The DBD is a highly conserved subunit that consists of two zinc-finger structures. In
each, a zinc atom is coordinated by four cysteine molecules. Two α-helices also contribute to
DNA-binding specificity and overall protein stability. The DBD has also been observed to be a
potent allosteric communicator to other parts of the NR, though precise mechanisms for
allosteric communication, especially involving the hinge region between LBD and DBD, remain
unclear. Finally, the DBD can in certain cases contribute a dimerization interface.
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Fig 1.5: DBDs of an Estrogen receptor dimer on DNA, showing a dimerization interface in the DBD.
Source: http://www.ks.uiuc.edu/Research/pro_DNA/ster_horm_rec/dbd/dbd_big.gif

The N-terminal regions beyond the DBD remain poorly understood. Atomic resolution of
these regions has not yet been achieved, however several biochemical assays have yielded hints
as to the structure and function of these domains. Several studies have shown these regions to be
mostly disordered, with little secondary structure. However, it has been seen that these regions
can adopt secondary structure under a variety of conditions, including DNA binding and
interaction with other transcription factors. Furthermore, this region contains several
phosphorylation regions that have been linked to its structural instability. Despite these insights,
an integrated understanding of the many possible functions of these N-terminal regions is still
not available. Similarly, the flexible hinge region between the LBD and DBD has also been
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noted to have several important phosphorylation sites, though the functional mechanisms of the
hinge remain unclear.

Fig 1.6: Diagram indicating phosphorylation sites of some isoforms of RAR and RXR. The N-terminus
harbors many phosphorylation sites. Source:http://www.nature.com/nrd/journal/v3/n11/images/nrd1551-i1.jpg

There are many open problems currently being pursued in NR research. Since the 90s the
field has amassed a great amount of information on the structure and function individual
subunits, and in some cases multiple subunits such as DBD-LBD complexes. One of the key
challenges moving forward is to integrate this data into the broader context of full-length
receptor function and interaction with other members of the transcription machinery. Full-length
atomic studies of NRs will be critical to understand allosteric communication within the
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receptors, and structural studies of NRs in complex with their interacting partners in the
transcription machinery will be necessary to achieve a detailed understanding of transcription in
general. Recent technological developments, particularly on the front of cryo-electron
microscopy which can now achieve near-atomic resolution of large (>100kD) complexes, should
speed progress on this front considerably.

Fig 1.7: Schematic overview of cryo-em as a tool for structural biology.
Source:http://media.americanlaboratory.com/m/20/Article/154443-fig3.jpg

Ultimately, work in this field will move toward a comprehensive understanding of how NRs
function within the larger context of transcription regulation, including allosteric mechanisms of
communication and interactions with transcription machinery.
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Fig 1.8: Illustration of the many factors involved in the larger transcription initiation machinery. Understanding the
interplay of all of these factors will be necessary for a comprehensive understanding of NR transcriptional activity.
Source: http://www.nature.com/nrm/journal/v6/n7/images/nrm1680-f2.jpg

This thesis will now briefly diverge from the biology of NRs to describe in detail two
biophysical techniques that were essential to the work herein presented. These techniques are
Small-angle X-Ray Scattering and Analytical Ultracentrifugation. An overview of the history of
the techniques will be presented, followed by a derivation of the basic physics behind the
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techniques, concluding with practical considerations for their application to the study of
biological molecules such as NRs.
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Physical Review: Small-angle X-ray Scattering
Through the course of the 19th century several different kinds of radiation were observed
and characterized, e.g. the discovery of infrared by Hershel in 1800, the discovery of ultraviolet
by Ritter in 1801, and the discovery of x-rays by Röntgen in 1895. It was Maxwell’s insights into
the mathematical description of the electromagnetic field which led to the understanding that
these forms of radiation are all disturbances in the electromagnetic field, thereby composing the
electromagnetic spectrum.
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The understanding of the electromagnetic spectrum allowed for a wide variety of
applications by using appropriate wavelength radiation to target specific interactions with matter.
X-rays were used in their first medical application only months after Röntgen’s discovery,
utilizing the fact that Calcium in bones strongly absorbs x-rays and therefore makes bones highly
visible in contrast to other biological matter.
As understanding of the nature of x-rays developed, so too did applications. A seminal
breakthrough was achieved by Paul Ewald and Max von Laue in 1912, when they postulated that
x-rays should have a wavelength conducive to the study of crystal spacings by diffraction. Von
Laue experimented with this idea by bombarding a crystal of copper sulfate with x-rays and
recording the resulting diffraction. Von Laue latter developed mathematical relations between
the scattering angles from the beam to the size and orientation of spacings between unit cells in
the crystal. This discovery led to a Nobel Prize in physics in 1914, and ushered in a century of
incredible discovery and development with crystallography.
William Bragg and his son together shared the Nobel Prize in Physics in 1915 for their
work on crystallographic analysis, which included the development of Bragg’s law. These
developments paved the way for structural determination of molecules by x-ray crystallography.
Simple organic molecules were first solved in the 1920’s, followed by larger molecules such as
cholesterol and penicillin. Finally, the age of protein crystallography was ushered in by the
determination of the structure of myoglobin by Sir John Kendrew in 1958.
Though much of the interest and focus of structural studies was on crystallographic
analysis, there was concurrent development on x-ray techniques that do not required highly
ordered samples. Guinier and Fournet were pioneers in Small-angle X-ray Scattering (SAXS)
studies, discovering in the 1930’s that analyzing scattering patterns of molecules in solution
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yielded information of the sizes, shapes, and internal structures of the molecules. This technique
remained of interest for samples that were impossible to crystallize, but was difficult to apply
more generally because of technological limitations. The 1970’s brought a revolution in smallangle scattering studies, as the development of synchrotrons provided much higher luminosity
beamlines for researchers. Initially, only a few general parameters about the particles, e.g. radius
of gyration and volume, were attainable from SAXS curves. The 1990’s brought another
revolution in SAXS through novel mathematical methods of analysis, which allowed ab initio
generation of envelope models of the particles to up to 10 angstrom resolution. Currently SAXS
is experiencing a strong revival of interest due to the powerful new techniques and software
available for structural analysis of scattering curves coupled with improving beamline
technology. Though much of the current work in SAXS now focuses on improvements in
engineering and application, there continue to be advances in the basic theory, as well.
A succinct overview of x-ray scattering theory will now be presented. A very general
diagram of a small-angle scattering experiment is provided:

Figure 2.1: Simple diagram of a scattering experiment setup.

A highly collimated plane wave of approximately .1nm x-rays is directed into the sample cell.
The electron clouds of the atoms in the sample scatter the waves elastically, and the resulting

Biophysical and Structural Characterization of Nuclear Hormone Receptors

14

waves are recorded on the detector plate. A beamstop is required to block the direct beam, which
is many orders of magnitude higher intensity than the scattered radiation.
To understand how reconstruction of particle properties can be obtained from a scattering
pattern, it is necessary to understand how x-rays interact with matter. There are several different
interactions that incident x-rays may have with matter, and we will classify these as elastic or
inelastic and coherent or incoherent. For elastic scattering, the incident plane wave causes
oscillation of electrons according to the electric component of the wave, creating an oscillating
electric dipole which radiates energy at an equal wavelength in an approximately spherical wave.
Inelastically, photons of the incident wave may collide with electrons causing a slight but
appreciable rebounding of the electron, which as a result radiates energy of a slightly different
wavelength. X-rays may also excite electrons to higher energy levels, which then radiate upon
following back down to a lower energy state, but do not in general radiate at the same
wavelength as the incident radiation. X-ray interactions with the nucleus are negligible and will
not be considered. Finally, a strong enough incident wave may ionize a sample via the
photoelectric effect, though this is also a negligible effect in most small-angle scattering studies.
We then characterize these interactions as coherent or incoherent, based on whether or not
information may be discerned from them. Coherent scattering is Thomson scattering, i.e.
radiation caused by dipole oscillation of electrons. Incoherent scattering comprises Compton
scattering, where an electron rebounds off of a photon, Absorption, the Photoelectric effect,
thermal fluctuations in the sample, and imperfections in sample homogeneity.
Finally, before we begin mathematical analysis of the scattering we must make an
approximation known as the Born approximation. Under this approximation we assume that the
incident beam is so many orders of magnitude more intense than the weak scattered waves that it
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is not appreciable changed as it passes through a sample, and therefore all scattering centers in
the sample are subject to the same beam. This approximation holds for most small-angle
scattering studies where the particles being studied are very weak scattering sources.
For a scattering experiment we define a differential scattering cross section as well as a
solid angle into which the incident radiation through the scattering cross section is scattered. We
define the scattering angle as the angle between the scattered and incident beam, and the
scattering length density, b, as a measure of the amplitude of a wave observed per unit incident
radiation in unit solid angle.

Figure 2.2: Diagram of the mathematical model used to describe scattering. Source: Serdyuk, Zaccai & Zaccai,
Methods in Molecular Biophysics, Cambridge University Press, 2007.

Biophysical and Structural Characterization of Nuclear Hormone Receptors

16

We require a single arbitrary origin to compare wave phases from different scattering sources,
and so with any arbitrary center we have the following diagram:

Figure 2.3: Modelling the contribution of distance from an arbitrary origin to the phase of the scattered waves.
Source: Serdyuk, Zaccai & Zaccai, Methods in Molecular Biophysics, Cambridge University Press, 2007.

Where O is the reference point. This allows us to calculate the phase differences between waves.
From the diagram we can see that:
𝛿=

2𝜋(𝑂𝑁 − 𝑂𝑀)
𝜆

So the scattered wave relative to O from an atom with scattering amplitude f can be written

𝐴 = 𝑓𝑒𝑥𝑝(𝑖𝛿)
Or, using wavevector notation and defining Q = k1 – k0

Biophysical and Structural Characterization of Nuclear Hormone Receptors

17

Figure 2.4: Wavevector notation, including the definition of scattering angle and q. Source: Serdyuk, Zaccai &
Zaccai, Methods in Molecular Biophysics, Cambridge University Press, 2007.

So that we have
𝐴 = 𝑓𝑒𝑥𝑝(𝑖𝑞 ⋅ 𝑟) where 𝑞 =

4𝜋 sin(𝜃)
𝜆

from the diagram

Extrapolating to many atoms is simple:
𝐹(𝑞) = ∑ 𝑓𝑗 exp(𝑖𝑞 ⋅ 𝑟)
This begs for a Fourier transform, so we acquiesce
𝑓(𝑟) = ∫ 𝐹(𝑞)exp(−𝑖𝑞 ⋅ 𝑟) 𝑑𝑉𝑞 and 𝐹(𝑞) = 𝑓(𝑟)exp ∫ (𝑖𝑞 ⋅ 𝑟) 𝑑𝑉𝑟
This would seemingly give us the scattering amplitude as a function of position, from which we
could deduce atomic coordinates. However we can only measure |F(q)|2 on the detector.
For a solution of non-interacting, monodisperse and homogeneous particles we have
𝐼𝑛 (𝑞) = ∑|𝐹𝑛 (𝑞)|2
But evidently this is not accurate because the particles in solution are in different orientations. To
solve this, we approximate that, given enough non-interacting particles, scattering from particles
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in different orientations is equivalent to scattering from a particle averaged over all orientations.
Therefore we calculate that:
< |𝐹(𝑞)|2 >=  ∑𝑗 ∑𝑘(𝑓𝑗 − 𝜌0 𝜈𝑗 )(𝑓𝑘 − 𝜌0 𝜈𝑘 )
𝐼𝑁 (𝑞) = 𝑁 ∑ ∑ 𝑚𝑗 𝑚𝑘
𝑗

𝑘

sin(𝑞𝑟𝑗𝑘 )
𝑞𝑟𝑗𝑘

→

sin(𝑞𝑟𝑗𝑘 )
𝑞𝑟𝑗𝑘

Where the terms 𝑓𝑗 − 𝜌0 𝜈𝑗 represent the contrast amplitude of the jth atom, and mj is shorthand
for this term. We can also write this:
𝐼𝑁 (𝑞) = 𝑁 ∬(𝜌(𝑟𝑗 ) − 𝜌0 )(𝜌(𝑟𝑘 ) − 𝜌0 )

sin(𝑞𝑟𝑗𝑘 )
𝑑𝜈𝑗 𝑑𝜈𝑘
𝑞𝑟𝑗𝑘

Or, normalized by concentration:
sin(𝑞𝑟𝑗𝑘 )
𝐼𝑁 (𝑞) 𝑁𝐴
=
∑ ∑ 𝑚𝑗 𝑚𝑘
𝐶
𝑀
𝑞𝑟𝑗𝑘
𝑗

𝑘

Where NA is Avogadro’s number, M is the molecular weight, and C is the concentration.
This forms the basic foundation for scattering theory.
Now we will look at mathematical developments that allow for intricate analysis of the
scattering curve. A major development came from Guinier, who noticed that the low-q part of
the curve fits well to a Gaussian:
1

1

𝐼(𝑞) = 𝐼(0) exp [− 3 𝑅𝑔2 𝑞 2 ] → ln(𝐼(𝑞)) = ln(𝐼(0)) − 3 𝑅𝑔2 𝑞 2
This allows for quick and simple determination of I(0) and Rg, as well as data quality validation
by analyzing the quality of the fit. The Guinier fit, as it is now described, is one of the most
valuable parameters extracted from a scattering curve, and therefore high quality low-q data is
very important.
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Now we turn to using the entire curve. Taking the inverse Fourier transform of I(q) we
get
1

∞

𝑉𝛾(𝑟) =  2𝜋2 ∫0 𝑞 2 𝐼(𝑞)

sin(𝑞𝑟)
𝑞𝑟

𝑑𝑞 where 𝛾(𝑟) =< (𝜌(𝑟𝑗 ) − 𝜌0 )(𝜌(𝑟𝑘 ) − 𝜌0 ) >

Where V is the volume of a single particle and 𝛾(𝑟) is the correlation function. From before we
had
𝐼𝑁 (𝑞) = 𝑁 ∬(𝜌(𝑟𝑗 ) − 𝜌0 )(𝜌(𝑟𝑘 ) − 𝜌0 )

sin(𝑞𝑟𝑗𝑘 )
𝑑𝜈𝑗 𝑑𝜈𝑘
𝑞𝑟𝑗𝑘

So now we can Fourier transform 𝑉𝛾(𝑟) to give
𝐼(𝑞) = 𝑉 ∫ 4𝜋𝑟 2 𝛾(𝑟)

sin(𝑞𝑟𝑗𝑘 )

𝑑𝑟 → 𝐼(𝑞) =  ∫ 𝑝(𝑟)

𝑞𝑟𝑗𝑘

sin(𝑞𝑟𝑗𝑘 )
𝑞𝑟𝑗𝑘

𝑑𝑟

Where p(r) = 4πr2Vγ(r) is the pairwise distribution function, so that now
∞
sin(𝑞𝑟𝑗𝑘 )
2
𝑝(𝑟) =  𝑟 2 ∫ 𝑞 2 𝐼(𝑞)
𝑑𝑞
𝜋
𝑞𝑟𝑗𝑘
0

However it is essential to note that this calculation requires values of I(q) at 0 and ∞, both of
which must be approximated. Now utilizing this information we can obtain:
𝐷𝑚𝑎𝑥

∫
0

𝑝(𝑟)𝑟 2 𝑑𝑟 = | ∫(𝑝(𝑟) −  𝑝0 )𝑑𝑣|2 = | ∑ 𝑚𝑗 |2 = 𝐼(0)

Where Dmax is the maximum dimension of the particle. We also obtain:
𝑅𝑔2

1 𝐷𝑚𝑎𝑥
𝑝(𝑟)𝑟 2 𝑑𝑟
∫0
2
=
𝐷𝑚𝑎𝑥
𝑝(𝑟) 𝑑𝑟
∫0

And the Porod invariant
∞

𝐶 =  ∫ 𝐼(𝑞)𝑞 2 𝑑𝑞
0

And finally the volume
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2𝜋 2 𝐼(0)
𝑉 =
𝐶
A good test of data quality is comparing the values obtained from I(0) and Rg obtained
from the Guinier approximation and integrating the pairwise distribution function. Large
discrepancies indicate poor data quality. By using the entire curve one can generate envelopes of
particles based on the pairwise distribution of scattering centers, though the mathematical models
for ab inito envelope reconstruction are beyond the scope of this review.
There are several factors that must be taken into account when preparing for an
experiment. For high-quality scattering data one should attempt to isolate a sample that is
monodisperse and homogeneous in both composition and conformation. Methods exist for
analyzing scattering from heterogeneous systems, but these analyses are more difficult and
should therefore be avoided if possible. A concentration series should also be used to extrapolate
out any interparticle effects that arise as a consequence of high concentration of particles. High
concentration solutions are required for high-q data, but will be most likely to experience interparticle effects or aggregation and should therefore be complimented with low-concentration
samples that can correct for these effects. Analyzing scattering data can be a highly subjective
process due to the relative lack of information in a scattering curve as compared to, e.g., a crystal
diffraction data set. Therefore, any additional data that may be obtained on the size, geometry,
mass, flexibility, and oligomeric state of the particles is very valuable towards constructive
SAXS analysis. Finally, radiation damage should be considered as a factor in the experiment.
The effect of radiation damage can be minimized by addition of compounds such as glycerol to
the buffer, and samples can be analyzed under multiple exposure times to check for radiation
damage.
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In an ideal experiment, a SAXS dataset on a monodisperse, homogeneous sample with a
broad concentration series range and no interparticle effects will return reasonably accurate
information on particle size, geometry, radius of gyration, volume, molecular weight, as well as a
molecular envelope up to a maximum resolution of 1nm. This information, especially when
coupled with data obtained via other methods e.g. crystallography or binding experiments, can
yield very valuable structural information on targets that are otherwise hard to analyze
structurally. SAXS therefore has a promising future in structural biology for analysis of
multimolecular complexes and disordered systems.

Physical Review: Analytical Ultracentrifugation
Analytical ultracentrifugation began its history with Theodore Svedberg’s work on gold
particles in the 1920’s. Svedberg was initially interested in calculating molecular weights of
colloidal gold particles using a gravitational sedimentation system coupled with an optical
observation system. Svedberg quickly realized that particles of sufficiently small size would
require much higher gravitational fields to be able to sediment appreciable, and this would
require a very powerful centrifuge. This led to the first design of an analytical centrifuge: a
centrifuge capable of achieving very high gravitational fields in the sample cell coupled to an
optical system for tracking particle motion. These first designs were largely unsuccessful,
however, due to poor sample cell design that allowed for convection to complicate the
hydrodynamics of the system. In 1924 Svedberg was able to design a centrifugal system that
minimized convection using sector-shaped cells, and it was around this same time that
Svedberg’s interests shifted from gold colloids to proteins, whose characteristics were still
almost entirely unknown at the time. In pioneering equilibrium studies on hemoglobin and
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albumin, Svedberg was able to make some essential observations: the molecular weight of the
molecules, and the homogeneity of the solutions, which hinted that proteins were large
macromolecules that could be identically reproduced in the cell. These observations constituted a
great advance in protein science, and yielded Svedberg the Nobel Prize in 1926. By the end of
the 1920’s, Svedberg and his colleagues had established analytical ultracentrifugation both in
theory and instrumentation as an extremely powerful technique for studying biological
molecules, though widespread use of the technique remained limited due to high cost and
insufficiently advanced instrumentation.
The next great advance in ultracentrifugation came after a massive increase in science
funding in the United States following the Second World War. In 1950’s a new ultracentrifuge
was unveiled: the Spinco model E. This centrifuge was much more versatile and user friendly
than the complicated Svedberg centrifuges, and was rapidly adopted by many labs. These
centrifuges allowed for a massive increase in the use of centrifugation techniques, and the next
two decades saw large accumulations of molecular data from ultracentrifugation techniques,
concurrent with advances in instrumentation, methodology, and theory.
The 1970’s and the advent of molecular biology techniques such as gel electrophoresis
and sequencing led to a very rapid decline in interest in ultracentrifugation. The technique
became expensive and difficult in comparison to simpler methods that sufficiently answered the
relevant questions of molecular weight and oligomeric status. While advances in theory and data
collection and acquisition continued, the use of ultracentrifugation as a technique in biochemistry
was rapidly dying. Two decades of incredible progress in ultracentrifugation were followed by
two decades of stagnation.
In 1992 Beckman introduced a new ultracentrifuge: the XL-A. The XL-A provided two
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essential improvements: a universal set of hardware and rapid digital data acquisition. This
centrifuge promised simple and rapid data acquisition and analysis. This led to a sudden
explosion of interest in analytical ultracentrifugation, contributing to an impressive rebirth of the
technique as one of the gold standards of biochemical and biophysical analysis. Further advances
in data analysis continued to improve the accessibility of analytical ultracentrifugation for
researchers, and the introduction in 1996 of the Beckman XL-I, which allowed for Raleigh
interference optics in addition to the standard absorption optics, provided ultracentrifugation with
the versatility required to compete with other techniques to be a valuable tool in the biochemist
and biophysicist’s arsenal.
Analytical ultracentrifugation has continued to advance in methodology, theory and
instrumentation over the years, now boasting a fluorescence optical system in addition to its
absorbance and interference systems, and programs to collect and analyze data continue to
improve and become more streamlined. Ultracentrifugation is currently taught in many graduate
programs as one of the essential tools for biochemical and biophysical studies of molecules, and
it is expected that ultracentrifugation will continue to be an invaluable tool for many years to
come.
Fundamentally, AUC is a simple technique based on the sedimentation of particles in a
solution when exposed to a centrifugal force. Balancing the forces yields equations that depend
on the particle mass and geometry and include the particle’s motion, therefore by following the
motion of a particle (or a boundary) it is possible to deduce molecular parameters of the sample.
To describe the motion in a sample cell, we use Fick’s diffusion equation with drift included:
𝐽𝑥 =  −𝐷

𝑑𝐶
+ 𝑢𝐶(𝑥)
𝑑𝑥

Biophysical and Structural Characterization of Nuclear Hormone Receptors

24

Where D is the diffusion coefficient, u is the angular velocity, C(x) is the concentration as a
function of x. But the velocity of the particle is dependent on the angular velocity of the cell, the
position of the particle, and a sedimentation coefficient, in other words 𝑢 = 𝑠𝜔2 𝑥 , so:
𝐽𝑥 =  −𝐷

𝑑𝐶
+ 𝑠𝜔2 𝑥𝐶(𝑥)
𝑑𝑥

But we must take into account the geometry of the sample cell. The relevant continuity equation
is that
𝑑𝐶
1 𝑑𝑟𝐽
𝑟 =−
𝑡
𝑑𝑡
𝑟 𝑑𝑟
So we ultimately obtain the Lamm equation:
𝑑𝐶
1 𝑑
𝑑𝑐
𝑟 =  − [ (𝜔2 𝑟 2 𝑠𝐶 − 𝐷𝑟 𝑡)] 𝑡
𝑑𝑡
𝑟 𝑑𝑟
𝑑𝑟
Analytical solutions of the Lamm equation are not attainable except under very specific
circumstances that are not particularly useful. However, several numerical methods exist to
approximate solutions, though these methods will not be described in detail.
The sedimentation coefficient computed from the Lamm equation solutions is an
extremely valuable experimental parameter. To see why, we need to examine how the
sedimentation coefficient relates to other parameters. We begin by examining the forces on the
sample, of which there are three: the centrifugal, the buoyant, and the frictional.
𝐹𝑐 = 𝑚𝜔2 𝑟
𝐹𝑏 = −𝑚0 𝜔2 𝑟
𝐹𝑑 = −𝑓𝑢
Where m, m0 are the masses of the sample and solvent displaced, r is the distance from rotor
center, u is the velocity of the molecule, f is the frictional coefficient, and ω is the angular
velocity. Equilibrium is obtained upon balancing forces, which gives
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𝑚𝜔2 𝑟(1 − 𝜈𝜌0 ) = 𝑓𝑢

Where ν is the partial specific volume of the molecule. On a mole basis
𝑠 ≔

𝑢
= 𝑀(1 − 𝜈𝜌0 )/𝑁𝐴 𝑓
𝜔2𝑟

This is the sedimentation coefficient, in units of seconds, and is one of the main values sought
after in an AUC experiment.
Modelling the boundary movement in terms of ρ, η, ν, and f/f0 allows a calculation of the
C(s) distribution, which sorts molecules in the sample by sedimentation coefficient, from which
can then be derived a C(M) distribution, which sorts molecules in the sample by molecular
weight, which is the approach used in SEDFIT.
An important consideration is that the sedimentation coefficient recorded in buffer must
be corrected for the standard values expected in water at 20 degrees Celsius, rather than buffered
solution at lower temperature.
𝑠20,𝑤 = 𝑠𝑒𝑥𝑝

1 − νρ20,𝑤 η𝑒𝑥𝑝
1 − νρ𝑒𝑥𝑝 η20,𝑤

Molecular mass may also be calculated from measurement of the sedimentation and
diffusion data, though it is prone to errors in measurement of the relevant values.
𝑠 𝑀(1 − νρ0 )
=
𝐷
𝑅𝑇
More accurate assessments of mass may be obtained from equilibrium experiments,
wherein the sample is centrifuged at a high speed for a long enough time to establish equilibrium
of the forces on the sample. This means that the total flux is 0, which means:
𝑑𝐶
𝑑𝑡

1

𝑟 =− [

𝑑

𝑟 𝑑𝑟

Rearranging we get

(𝜔2 𝑟 2 𝑠𝐶 − 𝐷𝑟

𝑑𝑐
𝑑𝑟

𝑑𝐶

𝑡)] 𝑡 = 0 → 𝐷( )𝑡 −  𝜔2 𝑟𝐶𝑠 = 0
𝑑𝑟
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dln(𝐶) 1 𝑑𝐶 𝜔2 𝑠 𝑀(1 − νρ)𝜔2
= 𝐶
=
𝑟2
𝑟 𝑑𝑟 𝐷
𝑅𝑇
𝑑 2
The concentration distribution falls off exponentially from the meniscus (a) and a point (r):
𝜔2 𝑀(1 − νρ)(𝑟 2 − 𝑎2 )
𝐶(𝑟) = 𝐶(𝑎) exp [
]
2𝑅𝑇
Plotting 𝑙𝑛(𝐶(𝑟)) vs 𝑟2/2 yields a straight line for a monodisperse solution, whose slope is
𝑀(1 − 𝜈𝜌0)𝜔2/𝑅𝑇. For a polydisperse solution, the tangential slope describes gives the average
molecular mass at that point in the cell.
These derivations have provided the relevant equations for basic analytical
ultracentrifugation experiments running either velocity or equilibrium setups. The programs
designed to handle the data acquisition and analysis are described elsewhere.
There are several practical considerations to take into account when setting up an
analytical ultracentrifugation experiment. One should first consider which setup, velocity or
equilibrium, will be most appropriate for the parameters being studied. Velocity experiments
provide information on particle mass, size, shape, and interactions, while equilibrium provides
highly accurate data on mass and interactions, and can also be used to test non-ideal behavior of
molecules. Next, rotor speeds should be chosen to best fit the system being studied. With prior
knowledge of macromolecular composition, optimal rotor speeds can be approximated based on
the relevant equations. For example, if either molecular weight or sedimentation coefficient of
the macromolecules can be estimated, then the optimal rotor speeds for an equilibrium
experiment can be calculated from the final equation provided above. Finally, buffer solutions
should be as close to water as feasible in order to minimize error in computing standard values
for the experimental parameters. Additions such as glycerol, due to its high viscosity, can
strongly contribute to error in the experiment.
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Results:
Agonist-Ligands Mediate the Transcriptional Response of Nuclear Receptor
Heterodimers through Distinct Stoichiometric Assemblies with Coactivators
ABSTRACT
The constitutive androstane (CAR) and retinoid X receptors (RXR) are ligandmediated transcription factors of the nuclear receptor protein superfamily. Functional
CAR:RXR heterodimers recruit coactivator proteins, such as the steroid receptor
coactivator-1 (SRC1). Here, we show that agonist ligands can potentiate transactivation
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through both coactivator binding sites on CAR:RXR which distinctly bind two SRC1
molecules. We also observe that SRC1 transitions from a structurally plastic to a compact
form upon binding CAR:RXR. Using small-angle X-ray scattering (SAXS) we show that the
CAR(tcp):RXR(9c)/SRC1 complex can encompass two SRC1 molecules compared to the
CAR(tcp):RXR/SRC1 which binds only a single SRC1. Moreover, sedimentation coefficients
and molecular weights determined by analytical ultracentrifugation (AUC) confirm the
SAXS model. Cell-based transcription assays show that disrupting the SRC1 binding site on
RXR alters the transactivation by CAR:RXR. These data suggest a broader role for RXR
within heterodimers while offering multiple strategies for the assembly of the transcription
complex.
Nuclear hormone receptors (NR) relay cellular signals through distinct multiprotein
assemblies (1). At the basic level, small-molecule signals produce structural changes within NRs
and these changes determine the composition of the interacting protein complex. These changes
are essential for transcriptional activity and appear to be conserved among all ligand-activated
receptors that have been studied to date. NRs are characteristically modular proteins with distinct
functional domains (2). At the N-terminus is the DNA binding domain (DBD) which determines
target-gene selectivity. The ligand-binding domain (LBD) is a multi-functional module that
contains the ligand-binding pocket, a dimerization interface that associates with the retinoid X
receptor (RXR) and a C-terminal ligand-dependent transactivation domain (AF2). Multiple
biochemical and structural studies on nuclear receptors have demonstrated that ligand binding
results in the specific conformational changes that are associated with a transcriptionally active
state (3). In this active state, the conformation of the AF2 domains typically rearrange along the
receptor surface, thereby creating a new docking site for transcriptional coactivator proteins (4).
Since both receptors within NR heterodimers can bind small-molecule agonist ligands, in the
simplest model for transactivation, agonist binding to either receptor can generate comparable
transcriptional levels of downstream genes. Furthermore, this model would predicate that the
presence of agonists to both receptors at once would yield proportionately higher levels of
transcription. Such model systems are exemplified by the CAR:RXR (Figure 1A), PPARα:RXR
and LXR:RXR heterodimers (5). Yet, there are NR heterodimers that exhibit transcriptional
responses that are distinct from this model (5,6). For instance, transactivation by RAR:RXR,
VDR:RXR and TR:RXR only occurs in the presence of the RAR, VDR and TR agonists, and when
used in combination with the RXR agonist, transactivation levels are either enhanced, unaffected
or are repressed, respectively (5,7). Through structural and biophysical studies, the mechanism of
transactivation has been recognized to occur through conformational changes that restrict
recruitment to a single coactivator protein to RAR:RXR (8) or decrease T3 agonist binding-affinity
to TR:RXR (7).
CAR is most abundantly expressed in the liver and intestine and has been directly linked
to the transcription of genes involved in the clearance of both xenobiotics (9-11), and endogenous
toxins such as bilirubin (12). These target genes include select P450 family monooxygenases,
phase II conjugating enzymes and xenobiotic transporters. Therefore, CAR serves as a master
regulator of xenobiotic clearance and its activation can be considered a form of chemical
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immunity. Within the nucleus, CAR binds to RXR and forms a functional heterodimer that
recognizes its specific target genes. Additionally, the transcriptional activity of CAR is induced
simply by association with RXR and with no apparent need for a CAR ligand (13-15). Although
ligand is not required for activation, constitutive CAR activity is mediated through the same
conserved functional domains as those utilized by ligand-activated receptors; thus the CAR:RXR
heterodimer recruits coactivator proteins through the AF2 transactivation domain (16,17).
Transactivation levels mediated by CAR:RXR can be augmented by agonist ligands such as 1,4bis[2-(3,5-dichloropyridyloxy)] benzene (tcp) (18) and 6-(4-cholorophenyl)imidazo[2,1b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO) (19), which are selective
for mouse and human CAR, respectively, while 9-cis retinoic acid (9c) can function as an RXR
agonist (20). In both cases, these agonists enhance constitutive activity by stabilizing the
constitutive AF2-coactivator interaction. Additionally, transactivation by the CAR:RXR
heterodimer can be potentiated by the RXR agonist, 9c (Figure 1A). 9c binds the ligand binding
pocket of RXR and evokes the canonical NR conformational changes that result in direct
interactions with coactivators. The SRC coactivator proteins function to recruit the cellular
transcriptional machinery to activated NRs (21,22). SRCs also play an essential role as histone
acetyltransferases to acetylate histone proteins and consequently enhance transcriptional activity
(23). Thus, there is a direct link between agonist ligand binding, coactivator recruitment and the
transcription of downstream genes.
The activity of permissive NR heterodimers such as CAR:RXR that is potentiated by
ligands to both CAR and RXR raises interesting questions about the precise structural assembly
of nuclear factors that promote such transactivation. In this study, we propose that with permissive
NR heterodimers represented by CAR:RXR, the levels of coactivator recruitment are proportional
to the liganded state of the heterodimer. Thus, CAR(tcp):RXR/SRC1 is a 1:1 NR:coactivator
complex while CAR(tcp):RXR(9c)/SRC1 exists in 1:2 binding stoichiometry. Moreover, these
levels of coactivator recruitment are proportional to transcriptional activity (Figure 1A). These
data further suggest that in this subset of NR heterodimers RXR performs a substantial role in
regulating transcriptional responses within the cell. Because of the polarity of the LXRE
DNA/CAR:RXR complex used in the transactivation assays (Experimental Procedures), CAR
occupies the 3’ half-site, directly upstream from the luciferase gene. Thus, a major role of the
coactivator molecule bound to CAR is to recruit the transcriptional machinery needed for
luciferase production.

EXPERIMENTAL PROCEDURES
Protein Expression and Purification
CAR:RXR was purified as described earlier (24,25). Briefly, the murine CAR LBD (residues
117−358) was subcloned into the pET15b vector with an N-terminal hexahistidine tag from mCAR
cDNA kindly provided by Dr. Barry M. Forman. The human RXRα LBD (residues 225−462) was
subcloned into the pACYC184 vector was a kind gift from Dr. Bruce Wisely (Glaxo Smith-Kline,
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Inc.). Residues 617-769 of SRC1 (Accession no. Q15788) encompassing three nuclear receptor
interacting motifs (RIDs) were subcloned into the pET-SUMO vector. CAR:RXR and SRC1 were
separately isolated by affinity chromatography column using Ni-NTA resin (Qiagen Inc.) To
prepare various CAR:RXR/SRC complexes, CAR:RXR and SRC(RID 1-3) were mixed in a 1:2
molar ratio, after the addition of ligands, and loaded onto an S200 Superdex 16/60 column for
purification of the resulting complexes (Figure E1). Fractions corresponding to the complexes
were pooled, measured by Bradford Assay, and concentrated for further analysis.

Analytical Ultracentrifugation
Aliquots of CAR:RXR and SRC RID 1-3 were thawed and mixed in various ratios (1:3, 1:1, 3:1),
incubated briefly with ligands, and analyzed on a Beckman XL ultracentrifuge. Both sedimentation
velocity and sedimentation equilibrium experiments were performed. Sedimentation equilibrium
was performed at 8-10ºC and 3 rotor speeds, while sedimentation velocity was run at 20ºC and
55,000rpm. Data was analyzed using SEDFIT and SEDPHAT (26). We calculate the parameters,
f/f0, frictional ratio; sw(20,w), sedimentation coefficient under standard conditions; and rmsd
which reports the quality fit of the solutions of the Lamm equations (26) to the data.
Small-angle X-ray Scattering
Measurements were recorded at several beamlines: SIBLYS at Laurence Berkeley National
Laboratory, DND-CAT at Argonne National Laboratory, and MACCHESS at Cornell. Data was
analyzed using the ATSAS software package (27) and ScÅtter. 3D model building was performed
using DAMMIN and MONSA (28) and visualized using Chimera. Kratky plots were calculated
for shape analysis (29,30). The theoretical values for spherical objects in the Vc-based Kratky plot
attain an ordinate maxima of 0.82, and for non-flexible scattering particles, 𝑞 2 ∗ 𝑉𝑐 = √3, where q
is the scattering vector (Å) and Vc is defined by the correlation length of the scattering particle as
the ratio of the zero angle scattering intensity, I(0), to its total scattered intensity (30).

Reporter gene assays
These assays were performed as reported earlier (31). Briefly, CV-1 cells were maintained in
DMEM/F-12 media containing 10% fetal bovine serum and 1000 U/ml penicillin and 1 mg/ml
streptomycin. Immediately prior to the assay, the media was changed to DMEM/F-12 with 10%
charcoal-dextran treated FBS and no antibiotics. Lipofectamine® (Invitrogen) was used to transfect
cells with 50 ng/well pCMX mCAR, 40ng/well pCMX-Gal4-RXR, 100 ng/well pCMV-TK-luc
containing three copies of the liver X receptor response element (LXRE) and 10 ng/well of pRL
CMV expressing renilla luciferase as an internal control. The cells were dispensed on 24-well
plates and ligands were added 24 hours post transfection. The ligand concentrations used were
-cis retinoic acid. After 48 hours, cells were lysed. Activity was
determined using the dual luciferase assay kit (Promega Inc.) following the manufacturer’s
instructions. The reported results are the average from three separate experiments.

Biophysical and Structural Characterization of Nuclear Hormone Receptors

31

Gal4-DBD assays: The E456K mutation was made on pCMX-Gal4DBD-hRXRLBD (gift from
Prof. Barry Forman). Transfection and assay was performed as described above with full-length
CAR and four copies of a Gal4 binding site (pUC8-MH100x4-TK-Luc).

RESULTS
CAR(tcp):RXR(9c)/SRC1 Assembles as a 1:2 Heterodimer:Coactivator Complex
To develop an understanding of how the transcriptionally active CAR:RXR assembles with
coactivators, we prepared CAR:RXR LBD and SRC1(RID1-3) in E. coli and isolated multiple
complexes of CAR:RXR/SRC1 (Supplementary Figure 1). Since CAR:RXR can also bind SRC1
in the absence of agonist, for the study here we isolated the complexes CAR:RXR/SRC1,
CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 representing the unliganded, singlyliganded and doubly-liganded CAR:RXR complexes, respectively. SRC1(RID1-3) used in these
studies comprises amino acids 617-769, and encompasses the three nuclear receptor interacting
domains (RIDs) (Supplementary Figure 1A). Also, SRC1(RID1-3) has previously been shown to
interact in a ligand-dependent manner with CAR:RXR (15,25). Using small-angle X-ray scattering
(SAXS), we have determined the global molecular assembly and structural properties of the
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 complexes (Figure 1 and
Supplementary Table 1). For comparisons, we also measured scattering from CAR(tcp):RXR(9c)
and SRC1 alone and the shapes of the scattering curves are distinct and typical of their molecular
size and flexibility. Therefore, the scattering curve of CAR:RXR heterodimer alone is
characteristic of folded protein, while the scattering curve of SRC alone is representative of
disordered proteins (Figure 1B). We applied Kratky analyses (29) and shape comparisons to
identify any noticeable difference in compactness between CAR(tcp):RXR/SRC1 and
CAR(tcp):RXR(9c)/SRC1. From these analyses we could conclude that the
CAR(tcp):RXR(9c)/SRC1 complex is more elongated and shows greater flexibility than
CAR(tcp):RXR/SRC1, which suggests the presence of a second SRC1 molecule within the
CAR(tcp):RXR(9c)/SRC1 particle. We also compare the I(0)-scaled and Vc-based Kratky
scattering curves which emphasize differences in size and geometry of the scattering particles
(Materials and Methods) (30). In the I(0)-normalized graphical plot, we compare the linearity and
negative slope of the scaled intensity versus scattering angle for the complexes (Figure 1B). The
I(0)-normalized scattering plot of CAR(tcp):RXR(9c)/SRC1 complex is more linear with a
sharper slope than the corresponding plots of either CAR(tcp):RXR/SRC1 or CAR:RXR/SRC1
complexes. This clearly suggests that CAR(tcp):RXR(9c)/SRC1 is a relatively more extended
molecule of higher molecular weight than the unliganded and singly-liganded complexes. From
the the Vc-Kratky plot using experimental SAXS data we are able to infer that CAR:RXR alone is
mostly spherical with no apparent flexibility, while free SRC1 shows a hyperbolic plateau that is
indicative of a highly flexible structure and with higher surface area-to-volume ratio (Figure 1C).
When comparing the heterodimer:coactivator complexes we note that there is a decrease in peak
height between CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 which further indicates that
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CAR(tcp):RXR(9c)/SRC1 is relatively extended particle (Figure 1C and Figure E1E). Overall, the
observed scattering pattern is consistent with the presence of a second SRC molecule in the
CAR(tcp):RXR(9c)/SRC complex. Furthermore, we note from a comparison of molecular
envelopes of free and bound SRC1 that this molecule adopts a relatively more compact structure
upon binding CAR:RXR, a feature that has been observed previously in the RAR:RXR/SRC1
complex (8).
To visualize the assembly of these complexes we generated molecular envelopes of
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 (Figure 1D, E & F). The
molecular shapes of CAR:RXR/SRC1 and CAR(tcp):RXR/SRC1 are of an elongated species and
are nearly identical at SAXS resolution (Figure 1E). The molecular shape of the
CAR(tcp):RXR(9c)/SRC1 complex is also elongated and is approximately 1.4-fold larger than the
CAR:RXR/SRC1 and CAR(tcp):RXR/SRC1 complexes (Figure 1E & F and Supplementary
Figure 1E). To depict the assembly of each complex, the molecular envelopes of the heterodimer
and coactivator were superimposed upon the envelope of each CAR:RXR/SRC1 complex. Both
manual and automated fitting (see Material and Methods) suggest that both the CAR:RXR/SRC1,
CAR(tcp):RXR/SRC1 envelopes can encompass the CAR:RXR heterodimer bound to a single
SRC1 molecule (Figure 1E). On the other hand, the molecular shape of CAR(tcp):RXR(9c)/SRC1
readily corresponds to a single CAR:RXR heterodimer that is bound to two SRC1(RID1-3)
molecules (Figure 1F and Supplementary Figure 2). Thus, these SAXS analyses suggest molecular
complexes of stoichiometries of 1:1 heterodimer:coactivator for the singly-liganded
CAR(tcp):RXR/SRC1 and 1:2 heterodimer:coactivator for and CAR(tcp):RXR(9c)/SRC
complexes.

Analytical Ultracentrifugation for Size Determination. To establish if the shapes of
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 correspond to their
relative sizes, these complexes were independently analyzed through sedimentation velocity and
equilibrium studies by analytical ultracentrifugation (AUC). The sedimentation velocity data
consistently shows a species of higher sedimentation coefficient with CAR(tcp):RXR(9c)/SRC1
than CAR(tcp):RXR/SRC1 (Figure 2A and Table 1). From sedimentation equilibrium analyses we
confirmed the molecular weights of these species to be 84.0 kDa (CAR:RXR/SRC1 and
CAR(tcp):RXR/SRC1) which corresponds to the size of one CAR:RXR heterodimer (55kDa)
bound to a single SRC1 (30kDa) and 113.0 kDa for the CAR(tcp):RXR(9c)/SRC1 complex, which
corresponds to one CAR:RXR heterodimer bound to two SRC1 molecules (Figure 2A and
Supplementary Figure 3). The equilibrium data therefore suggests a strong preference for 2:1
complex formation in the doubly-liganded state. Taken together, the ultracentrifugation data
confirm that the molecular envelopes determined by SAXS correspond to the molecular weights
of these complexes as determined by AUC. Therefore, we hypothesize that transactivation by
CAR(tcp):RXR(9c)/SRC1 is relies on coactivator binding to both CAR and RXR.

Transactivation by CAR:RXRE456K is Distorted from the Native CAR:RXR Complex
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There are multiple factors within the cell that function to regulate transactivation by NRs (32,33).
Of these factors, the SRC family of coactivator proteins are recruited specifically to the agonistbound conformation of the NR LBD (34). In this agonist-bound conformation the AF2 domain is
realigned along the receptor surface, and in doing so creates a new interface that can bind SRC
proteins (35). The amino acid E456 is within the AF2 domain of RXR and interacts with SRC1
(16). To better understand the role of the RXR coactivator binding site within CAR:RXR, we
compare the transactivation of CAR:RXRE456K with the native protein complex in a cell-based
reporter system. This E→K amino acid substitution has previously been shown to disrupt SRC1
recruitment by RXR (36). When tested in CV1 cells, we notice that the transcriptional response of
CAR:RXR and CAR:RXRE456K to tcp (relative to no exogenous ligand) is similar with no
noticeable allosteric effects of the RXRE456K mutation on CAR. However, transactivational levels
in response to exogenously applied 9c alone (Figure 2B) and to the combination of 9c+tcp by the
native CAR:RXR and mutant CAR:RXRE456K receptor complexes are markedly different
(Supplementary Figure 4). The measurements of SAXS and AUC above propose a distinct role for
RXR within the CAR:RXR complex. Together, these results suggest that in CAR:RXR the SRCbinding site within RXR is essential for the heterodimer to achieve maximum transcriptional
activity. Thus, relative to other NR heterodimers such as RAR:RXR and VDR:RXR (8,37), RXR
can undertake a more significant role in transactivation by CAR:RXR.
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Figure 1. Activity and assembly of CAR:RXR. (A). Transactivation of CAR:RXR measured in CV-1 cells on 3
copies of LXRE. (B) Scattering curve normalized to I(0) to show differences in size and deviation from globular
shape. Blue, SRC1; cyan, CAR:RXR; Orange, CAR:RXR/SRC1, purple, CAR(tcp):RXR/SRC1; green,
CAR(tcp):RXR(9c)/SRC1. (C) Vc based Kratky plot for visualization of flexibility and surface area-to-volume ratio.
Molecular shapes of the complexes are generated by MONSA, while the individual heterodimer and coactivator
envelopes are generated by DAMMIN. (D) Top, molecular shape of free SRC1(RID1-3); bottom, molecular shape of
CAR(tcp):RXR(9c). (E) & (F) Molecular shapes of CAR(tcp):RXR/SRC and CAR(tcp):RXR(9c)/SRC (light grey),
respectively.
Superimposed on this is the SRC (dark grey spheres) envelope from (D) and the
CAR:RXR/SRC(peptide, green) structure (PDB ID:1XLS). Molecular envelopes are produced by DAMMIN from
SAXS data.
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Figure 2. Activity of CAR and SRC1 mutants. (A). Sedimentation coefficients from sedimentation velocity
experiments using AUC. Molecular weights shown above each peak are in kDa (See also Table 1 and Figure S2). (B).
Transactivation by CAR:Gal4 DBD-RXR LBD and CAR:Gal4 DBD-RXRE456K LBD measured in CV-1 cells on four
copies of a Gal4 binding site (mh100x4-tk-luc) response element. C. Models of the NR transactivation complexes.
Top, CAR:RXR/SRC1, CAR(tcp):RXR/SRC1. Bottom, CAR(tcp):RXR(9c)/SRC1.
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Molecular Species

f/fo

sw(20,w)

rmsd

CAR:RXR

1.28

4.12

0.005

SRC1

1.5

2.1

0.007

CAR:RXR/SRC

1.46

2.27, 4.7

0.007

CAR(tcp):RXR/SRC

1.46

2.4, 4.7

0.006

CAR:RXR(9c)/SRC

1.5

2.48, 5.69

0.006

CAR(tcp):RXR(9c)/SRC

1.5

2.27, 5.6

0.009

Table 1: AUC velocity data. f/f0, frictional ratio; sw(20,w), sedimentation coefficient under standard conditions; rmsd
reports the quality fit to the data. A higher sedimentation coefficient for 9c and tcp+9c complexes indicates a larger
species, while a slightly higher frictional coefficient indicates a more extended structure.

DISCUSSION
Nuclear receptors are a superfamily of structurally and functionally conserved proteins that
have evolved to regulate transcription in response to small-molecule ligands through multiprotein
assemblies. Hormonal agonist molecules evoke the correct structural changes within NRs to
interact directly with coactivators, such as SRC1. Normal transactivation is dependent on the
precise assembly of the component molecules. However, there is only a superficial mechanistic
understanding of how this multiprotein assembly takes place, how it can be modulated and how it
relates to transactivation. The study here illustrates the role of the agonist ligand in defining the
molecular assembly of the NR:coactivator complex (Figure 2C).
Both, CAR and RXR in the CAR:RXR heterodimer can independently bind their respective
agonists (24). Also, crystallographic studies have shown that CAR(agonist):RXR(agonist) can
bind two 13-mer LXXLL coactivator-derived peptides through binding sites on both CAR and
RXR (16,17). This structural assembly has also been observed in other permissive NR
heterodimers such as LXR:RXR (38) and
(39). It is now clear from our data that
these LXXLL motifs that are bound to permissive NR heterodimers are derived from two
independent SRC1 molecules, although the intact SRC1 molecule has three distinct LXXLLcontaining RIDs (40).
This agonist-mediated heterodimer:coactivator stoichiometry has important mechanistic
implications for transactivation and in pharmacology. First, among the several functions ascribed
to SRCs are the recruitment of the cellular transcriptional machinery to activated NRs (21,22,41)
and as histone acetyltransferases (23). The polarity of heterodimers such as CAR:RXR on the
direct repeat response element places CAR towards the 3’ end of the promoter (42-44). Therefore,
the most likely function of the coactivator molecule bound directly to CAR is to assemble the
transcriptional machinery through interactions with p300/CBP (22). The addition of 9c to
permissive NR heterodimers allows for the recruitment of a second SRC coactivator molecule
directly to RXR on the 5’ end of the promoter. From this location, the second SRC can function
as and recruit other histone acetyltransferases thereby enhancing transactivational levels, as
observed with the progesterone and glucocorticoid receptors (45) (Figure 2C). Second, this
mechanism of transactivation is a distinct alternative to that proposed for the RAR:RXR
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heterodimer (8,37,46). In RAR:RXR, a single coactivator molecule is recruited directly to RAR
upon activation by agonist in a conformation similar to CAR(tcp):RXR/SRC. However, the
recruitment of a second coactivator to RAR(agonist):RXR(agonist) is restricted through longrange, agonist-induced conformational changes that disrupt the RXR coactivator-binding site (47).
Third, targeting coactivators for therapy is of growing interest (48,49), thus requiring a detailed
knowledge of such binding events. These coactivators display different binding specificities for
the receptors both independently (50) and within the heterodimer (15), thus, it is likely that the
specific interactions between each SRC1 molecule and the two binding sites on CAR:RXR are
distinct. The activation of CAR:RXR is not always beneficial as hepatic metabolism can convert
certain therapeutic drugs to potent toxins. For instance, CAR:RXR-mediated metabolism of
acetaminophen results in a reactive quinone metabolite (N-acetyl-p-benzoquinone imine). This
metabolic by-product promotes acute liver failure by binding to cellular macromolecules and by
generating reactive oxygen species (10,51). The hepatotoxic effects of cocaine are also mediated
via a CAR:RXR–dependent pathway (9). Thus, the activity of CAR:RXR can have either
protective or deleterious consequences to the organism depending on the particular chemical
challenges faced by it. Also, the discoveries of endogenous RXR ligands such as polyunsaturated
fatty acids (52-54) increase the likelihood of two agonists binding the CAR:RXR heterodimer at
once. Thus, this novel assembly has important implications for the design of small molecules
directed at regulating transactivation by modulating the formation and composition of the NRcoactivator assembly.
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